Researchers have developed antibody that can save cancerous bones

At the Finsen Laboratory, BRIC, and the DNRF Danish–Chinese Centre for Proteases and Cancer at Rigshospitalet a research group lead by Dr. Niels Behrendt and Dr. Lars Engelholm now shows that OS cells degrade the bone tissue through a completely different process than metastasised bone cancer. Through treatment with a specific antibody, the researchers blocked the process and reduced up to 80% of bone degradation in a cancer mouse model. Future treatment of OS patients with this type of antibody could reduce amputations among young patients and future studies will clarify if such a treatment strategy will also block lethal spreading of the OS cells to other organs.

Lars Engholm“By treating mice with OS with the new antibody, we could block the micro processes OS cells use to degrade the bones and thereby effectively protect the bone tissue”, explains Lars Engelholm

Niels BehhrendtA large proportion of new targeted cancer therapies are based on antibodies. We developed this antibody for basic studies of the molecule uPARAP, but when we discovered shown that this molecule is upregulated in OS tumours, we became interested in the possible treatment effect”, says Niels Behrendt.

The study was funded by the Danish Medical Research Council, the Danish Cancer Society, Novo Nordisk Foundation, Lundbeck Foundation and Danish National Research Foundation under the programme Danish–Chinese Centre for Proteases and Cancer.

Read more via University of Copenhagen



Newsletter